Hormone replacement therapy in breast cancer patients and survivors.
Menopause is arguably the most important phase of a woman's social, physiologic, and personal life. Approximately 1.3 million women reach this age in the United States annually. In the past decade, numerous studies have correlated breast cancer and the use of ERT (estrogen replacement therapy) or HRT (hormone replacement therapy) in menopausal women. Whether this is an actual increase in the creation of new cancers or a result of a diagnostic or other bias has yet to be determined. Even more uncertainty surrounds the use of hormones once breast cancer is diagnosed. Previously, once a woman was diagnosed with an estrogen-dependent tumor, ERT and HRT were simply forbidden. As discussed herein, that is no longer the case.
Del Priore
Giuseppe
G
Department of Gynecologic Oncology, New York University School of Medicine, NY 10016, USA. Info@CancerandFertility.org
Hatami
Mehrangiz
M
D001943:Breast Neoplasms / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors; D017741:Survivors